Show simple item record

dc.contributor.authorde Faria E Silva, Ana Luiza
dc.contributor.authorElcoroaristizabal, Saioa
dc.contributor.authorRyder, Alan G.
dc.date.accessioned2020-07-17T12:42:58Z
dc.date.available2020-07-17T12:42:58Z
dc.date.issued2020-07-07
dc.identifier.citationde Faria e Silva, Ana Luiza, Elcoroaristizabal, Saioa, & Ryder, Alan George. (2020). Characterization of lysozyme PEGylation products using polarized excitation-emission matrix spectroscopy. Biotechnology and Bioengineering. doi:10.1002/bit.27483en_IE
dc.identifier.issn1097-0290
dc.identifier.urihttp://hdl.handle.net/10379/16084
dc.description.abstractThe growing use of therapeutic proteins requires accurate measurement techniques for measuring biophysical and structural changes during manufacturing. This is particularly true for PEGylation of proteins, because characterization of PEGylation reactions and products can often be difficult because of the relatively small impact on protein structure, the lack of an accessible PEG chromophore, and the heterogeneous final product mixtures. Intrinsic fluorescence spectroscopy is one potential solution because of its relatively high sensitivity to small changes in protein structure and its suitability for online or at-line measurements. Here we use PEGylation of lysosome as a model system to determine the efficacy of polarized Excitation Emission Matrix (pEEM) spectroscopy as a rapid tool for characterizing the structural variability of the lysozyme starting materials and PEGylated products with PEG to protein ratio (PPR). Dynamic Light Scattering (DLS) showed that as PPR increased from 0 to 2.8, the hydrodynamic radius increased from ~2.2 to 4.8 nm. pEEM measurements provided several sources of information: Rayleigh scatter identified size changes and aggregate/particle formation, and fluorescence emission to assessed chemical and structural change. PEGylation induced sufficient physicochemical changes in lysozyme which produced changes in the pEEM spectra largely due to changes in hydrophobic environment for tryptophan residues close to a PEG attachment site. These significant spectral changes when modelled using conventional multivariate analysis methods were able to easily discriminate the raw product solutions according to degree of PEGylation and were also able to predict PPR with reasonable accuracy (RMSEC ~10%, REPen_IE
dc.description.sponsorship14/IA/2282, Advanced Analytics for Biological Therapeutic Manufacture, Science Foundation Ireland (SFI) with co-funding under the European Regional Development Fund. This publication has emanated from research supported in part by a research grant from Science Foundation Ireland (SFI) and is co-funded under the European Regional Development Fund under Grand number (14/IA/2282, Advanced Analytics for Biological Therapeutic Manufacture, to AGR). We also thank Agilent Technologies (Mulgrave Victoria, Australia) for the loan of a fluorescence spectrometer. The authors declare that there are no conflicts of interest.en_IE
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.publisherWileyen_IE
dc.relation.ispartofBiotechnology and Bioengineeringen
dc.subjectProteinen_IE
dc.subjectLysozymeen_IE
dc.subjectPEGylationen_IE
dc.subjectFluorescenceen_IE
dc.subjectPolarizeden_IE
dc.titleCharacterization of Lysozyme PEGylation products using polarized Excitation Emission Matrix (pEEM) spectroscopyen_IE
dc.typeArticleen_IE
dc.date.updated2020-07-15T17:03:07Z
dc.identifier.doi10.1002/bit.27483
dc.local.publishedsourcehttps://doi.org/10.1002/bit.27483en_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funderScience Foundation Irelanden_IE
dc.contributor.funderEuropean Regional Development Funden_IE
dc.description.embargo2021-07-07
dc.internal.rssid21850539
dc.local.contactAlan Ryder, School Of Chemistry, Room 213, Arts/Science Building, South Cam, Nui Galway. 2943 Email: alan.ryder@nuigalway.ie
dc.local.copyrightcheckedNo
dc.local.versionACCEPTED
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Investigator Programme/14/IA/2282/IE/Advanced Analytics for Biological Therapeutic Manufacture (AA-BTM)./en_IE
nui.item.downloads0


Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:

Thumbnail

This item appears in the following Collection(s)

Show simple item record